Patient characteristics and treatment considerations in pancreatic cancer: a population based study in the Netherlands

References

• Royal R. Cancer of the pancreas. Cancer principles and practice of oncology. Vol. 9. Philadelphia: Lippincott William & Wilkins; 2011.
   Google Scholar
• Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389:1011–1024.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–1825.
   PubMed Web of Science ®Google Scholar
• SEER Cancer Statistics Review, 1975-2014. [Internet]. Bethesda: National Cancer Institute; [based on November 2016 SEER data submission, posted to the SEER web site, April 2017]. Available from: https://seer.cancer.gov/csr/1975_2014/
   Google Scholar
• Goldstein D, El-Maraghi RH, Hammel P, et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015;107.DOI:https://doi.org/10.1093/jnci/dju413
   Google Scholar
• Carmichael J, Fink U, Russell RC, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 1996;73:101–105.
   PubMed Web of Science ®Google Scholar
• Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994;12:29–34.
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–2413.
   PubMed Web of Science ®Google Scholar
• Clarke G, Johnston S, Corrie P, et al. Withdrawal of anticancer therapy in advanced disease: a systematic literature review. BMC Cancer. 2015;15:892.
   PubMed Web of Science ®Google Scholar
• Schildmann J, Tan J, Salloch S, et al. “Well, I think there is great variation…”: a qualitative study of oncologists' experiences and views regarding medical criteria and other factors relevant to treatment decisions in advanced cancer. Oncologist. 2013;18:90–96.
   PubMed Web of Science ®Google Scholar
• Bernards N, Haj Mohammad N, Creemers GJ, et al. Ten weeks to live: a population-based study on treatment and survival of patients with metastatic pancreatic cancer in the south of the Netherlands. Acta Oncologica. 2015;54:403–410.
   PubMed Web of Science ®Google Scholar
• Ziebland S, Chapple A, Evans J. Barriers to shared decisions in the most serious of cancers: a qualitative study of patients with pancreatic cancer treated in the UK. Health Expect. 2015;18:3302–3312.
   PubMed Web of Science ®Google Scholar
• King JC, Zenati M, Steve J, et al. Deviations from expected treatment of pancreatic cancer in octogenarians: analysis of patient and surgeon factors. Ann Surg Oncol. 2016;23:4149–4155.
   PubMed Web of Science ®Google Scholar
• Bilimoria KY, Bentrem DJ, Ko CY, et al. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246:173–180.
   PubMed Web of Science ®Google Scholar
• Kao S, Shafiq J, Vardy J, et al. Use of chemotherapy at end of life in oncology patients. Ann Oncol. 2009;20:1555–1559.
   PubMed Web of Science ®Google Scholar
• Krzyzanowska MK, Weeks JC, Earle CC. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol. 2003;21:3409–3414.
   PubMed Web of Science ®Google Scholar
• Bjerregaard JK, Mortensen MB, Schonnemann KR, et al. Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients. Eur J Cancer. 2013;49:98–105.
   PubMed Web of Science ®Google Scholar
• Fritz AP, C. Jack A. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organisation; 2000.
   Google Scholar
• Sobin LH. TNM classification of malignant tumors, 7th ed. Oxford: Wiley-Blackwell; 2009.
   Google Scholar
• Duijn CK, I. Sociaal-economische status indicator op postcode niveau [Socio-economic status indicator at postcode level]. Maandstat Bevolking Volksgezond. 2002;50:32–35. Dutch.
   Google Scholar
• Sharp L, Carsin AE, Cronin-Fenton DP, et al. Is there under-treatment of pancreatic cancer? Evidence from a population-based study in Ireland. Eur J Cancer. 2009;45:1450–1459.
   PubMed Web of Science ®Google Scholar
• Seal B, Xia F, Germino R, et al. An evaluation of national treatment trends in pancreatic cancer. J Clin Oncol. 2014;32(Suppl15):e15211.
   Web of Science ®Google Scholar
• Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7:593–600.
   PubMed Web of Science ®Google Scholar
• Mallinson CN, Rake MO, Cocking JB, et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. BMJ. 1980;281:1589–1591.
   PubMed Web of Science ®Google Scholar
• Palmer KR, Kerr M, Knowles G, et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg. 1994;81:882–885.
   PubMed Web of Science ®Google Scholar
• Tariman JD, Berry DL, Cochrane B, et al. Physician, patient, and contextual factors affecting treatment decisions in older adults with cancer and models of decision making: a literature review. Oncol Nurs Forum. 2012;39:E70–E83.
   PubMedGoogle Scholar
• Kashaf MS, McGill E. Does shared decision making in cancer treatment improve quality of life? A systematic literature review. Med Decis Making. 2015;35:1037–1048.
   PubMed Web of Science ®Google Scholar
• Schildmann J, Ritter P, Salloch S, et al. 'One also needs a bit of trust in the doctor … ': a qualitative interview study with pancreatic cancer patients about their perceptions and views on information and treatment decision-making. Ann Oncol. 2013;24:2444–2449.
   PubMed Web of Science ®Google Scholar
• Tariman JD, Berry DL, Cochrane B, et al. Preferred and actual participation roles during health care decision making in persons with cancer: a systematic review. Ann Oncol. 2010;21:1145–1151.
   PubMed Web of Science ®Google Scholar
• Brom L, De Snoo-Trimp JC, Onwuteaka-Philipsen BD, et al. Challenges in shared decision making in advanced cancer care: a qualitative longitudinal observational and interview study. Health Expect. 2017;20:69–84.
   PubMed Web of Science ®Google Scholar
• Buiting HM, Brink M, Wijnhoven MN, et al. Doctors' reports about palliative systemic treatment: a medical record study. Palliat Med. 2017;31:239–246.
   PubMed Web of Science ®Google Scholar
• Baxter NN, Whitson BA, Tuttle TM. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol. 2007;14:1320–1326.
   PubMed Web of Science ®Google Scholar
• van Roest MH, van der Aa MA, van der Geest LG, et al. The impact of socioeconomic status, surgical resection and type of hospital on survival in patients with pancreatic cancer. A population-based study in the Netherlands. PloS One. 2016;11:e0166449.
   PubMed Web of Science ®Google Scholar
• Louwman WJ, Aarts MJ, Houterman S, et al. A 50% higher prevalence of life-shortening chronic conditions among cancer patients with low socioeconomic status. Br J Cancer. 2010;103:1742–1748.
   PubMed Web of Science ®Google Scholar
• Zijlstra M, Bernards N, de Hingh IH, et al. Does long-term survival exist in pancreatic adenocarcinoma? Acta Oncologica. 2016;55:259–264.
   PubMed Web of Science ®Google Scholar
• Ducreux M, Cuhna AS, Caramella C, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26: v56–v68.
   PubMed Web of Science ®Google Scholar
• Ho TH, Barbera L, Saskin R, et al. Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol. 2011;29:1587–1591.
   PubMed Web of Science ®Google Scholar
• Klapdor R. Perspectives in chemotherapy of pancreatic cancer. Eur J Surg Oncol. 1991;17:153–166.
   PubMed Web of Science ®Google Scholar
• Adsersen M, Thygesen LC, Jensen AB, et al. Is admittance to specialised palliative care among cancer patients related to sex, age and cancer diagnosis? A nation-wide study from the Danish Palliative Care Database (DPD). BMC Palliat Care. 2017;16:21.
   PubMed Web of Science ®Google Scholar
• Fest J, Ruiter R, van Rooij FJ, et al. Underestimation of pancreatic cancer in the national cancer registry - reconsidering the incidence and survival rates. Eur J Cancer. 2017;72:186–191.
   PubMed Web of Science ®Google Scholar
• Kotronoulas G, Kearney N, Maguire R, et al. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol. 2014;32:1480–1501.
   PubMed Web of Science ®Google Scholar
• Coebergh van den Braak RRJ, van Rijssen LB, van Kleef JJ, et al. Nationwide comprehensive gastro-intestinal cancer cohorts: the 3P initiative. Acta Oncologica. 2018;57:195–202.
   PubMed Web of Science ®Google Scholar